Premenstrual symptoms include a constellation of mood, behavioral, and physical indications that occur in a cyclic pattern prior to menstruation and then wane off after the menstrual period in women of reproductive age. Most females have only mild discomfort, and symptoms do not interfere with their personal, social, or professional live; however, 5% to 8% of women have moderate-to-severe symptoms that can cause significant distress and functional impairment.
Although premenstrual symptoms have been recognized for a long time, the diagnostic criteria have been specified only recently. The nomenclature for premenstrual disorders has changed significantly over the years, evolving from "menses moodiness" in the 18th century to "premenstrual tension" in the early part of 19th century to finally "premenstrual syndrome" in the 1950s. While some discomfort prior to menses is quite common, premenstrual syndrome (PMS) includes the subset of women who experience symptoms that are severe enough to impact daily activities and functioning. Late luteal dysphoric disorder (LLDD), now known as premenstrual dysphoric disorder (PMDD), accounts for the most severe form of PMS with the greatest impairment of women’s functioning and perceived quality of life, often prompting them to seek treatment.
Currently, PMDD is listed in Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) as a separate entity under Depressive disorders, with the criteria for diagnosis as follows:
Criterion A - At least 5 of the following 11 symptoms (including at least 1 of the first 4 listed) should be present:
Criterion B - symptoms severe enough to interfere significantly with social, occupational, sexual, or scholastic functioning.
Criterion C - symptoms discretely related to the menstrual cycle and must not merely represent an exacerbation of the symptoms of another disorder, such as major depressive disorder, panic disorder, dysthymic disorder, or a personality disorder (although the symptoms may be superimposed on those of these disorders).
Criterion D - criteria A, B, and C confirmed by prospective daily ratings during at least 2 consecutive symptomatic menstrual cycles. The diagnosis may be made provisionally before this confirmation.
Women with moderate-to-severe PMS or PMDD experience more quality-of-life detriments, work-productivity losses, and incur greater healthcare costs than women with no or only mild symptoms.
The exact etiology of PMS/PMDD is not known. There are, however, risk factors associated with the development of PMS/PMDD, some of which are well-established while others are speculative.
Proven Risk Factors
Speculative Risk Factor
Premenstrual symptoms can affect all women in reproductive age, ranging from menarche till menopause. Premenstrual symptoms are a common problem for women in the reproductive age group. In the United States, approximately 70% to 90% of women in the reproductive age group complain of at least some premenstrual discomfort. Approximately one-third of these women have symptoms that are bothersome enough to qualify for the diagnosis of PMS. The most severe form of premenstrual symptom complex, PMDD, has been noted in 3% to 8% of these PMS cases.
In a study by Halbreich et al., women in the US have about 481 menstrual cycles during this lifespan. Taking into account the 22 months for two pregnancies and postpartum periods, many women roughly experience 459 cycles during their childbearing years. Also, US women with PMDD experience an average of 6.4 days of severe symptoms per menstrual cycle; this is approximately equivalent to 8 years of debilitating symptoms throughout the menstrual cycle. Examining the numbers leads one to the certainty that PMS or PMDD can cause distress and functional impairment over a significant duration of a woman’s lifetime, making it an important health problem.
Recent evidence from research studies suggests that reproductive hormone release patterns are normal in women with PMS/PMDD, but they have a heightened sensitivity to cyclical variations in levels of reproductive hormones which predisposes them to experience the mood, behavioral, and somatic symptoms.
Role of Sex Steroids
Many scientists have postulated that PMS/PMDD symptoms develop because of a decline of progesterone in the late luteal phase that causes CNS changes in gamma-aminobutyric acid (GABA) and progesterone metabolites that interact with the GABA-A receptor complex. However, there are other sets of scientists who argue against this hypothesis by stating that in many women symptoms can begin at ovulation and early luteal phase before the fall in the level of progesterone. To further corroborate, some studies showed that the hormonal cyclicity was suppressed by treatment with Gonadotropin-releasing hormone and re-exposure to progesterone reproduced symptoms even when the hormone concentrations were stable. Also, if the above theory of decline in the late luteal phase indicating progesterone as the precipitating factor were to be believed then administration of progesterone during this phase would have been an effective treatment which is not.
Allopregnanolone is a metabolite of progesterone, and like progesterone, levels of this metabolite also fluctuate during the menstrual cycle. As mentioned, progesterone metabolites interact with GABA-A receptor complex and allopregnanolone specifically potentiate inhibitory responses to GABA-A receptor agonists. Some studies suggest that women with PMS/PMDD have diminished functional sensitivity of the GABA-A receptor due to deficient allopregnanolone response to stress.
An alternative hypothesis suggests that preovulatory peak in estradiol, postovulatory increase in progesterone, or both trigger symptoms of PMS/PMDD; however, a shortcoming of this theory is its failure to explain why symptoms start with ovulation for some women but in late luteal phase for others. It has also been reported that estrogen is as efficacious as progesterone in provoking PMS-like complaints and the estrogen component of hormone replacement therapy can amplify progesterone-induced dysphoria. Besides, the administration of estrogen in the luteal phase has been reported to provoke premenstrual symptoms and giving estrogen antagonist in the luteal phase decreases premenstrual mastalgia.
Role of Central Neurotransmitters
Serotonin is a central neurotransmitter that is well proven to be involved in mood and behavior regulation. Sex steroids may affect behavior by exerting their effects on serotonergic transmission. Three proofs authenticate this theory. First, premenstrual symptoms are diminished by serotonin reuptake inhibitors (SRIs) and other treatments that boost serotonin levels, like serotonin- releasing agents.. Second, contrary to the first point, a decrease in the serotonergic transmission achieved by a tryptophan-free diet or by treatment with a serotonin-receptor antagonist can give rise to PMS/ PMDD symptoms. Third, women with PMS/PMDD have atypical serotonergic transmission and lower density of serotonin transporter receptors than typical women. In addition, they have a higher level of serotonergic responsiveness in the follicular than in the luteal phase, which is different from that observed in women without PMS/PMDD.
GABA is an inhibitory neurotransmitter, and some imaging studies suggest the possible role of GABA in the pathophysiology of PMS/PMDD based on the fact that some progesterone metabolites interact with GABA A receptor, and that symptomatic women have a different responsiveness of this receptor complex as compared to asymptomatic women. Another noteworthy fact is that GABAergic and serotonergic neurons have meaningful interactions and thus the role of GABA in the pathophysiology of PMS/PMDD is in keeping with the serotonin hypothesis. Additionally, SRIs also strongly influence enzymes involved in creating progesterone metabolites which in turn modulate GABA A receptors.
Glutamate is an excitatory neurotransmitter, and there is a cyclical fluctuation in its levels during the menstrual cycle for all women (symptomatic and asymptomatic), but symptomatic women seem to have an increased sensitivity to these cyclical changes.
Studies have shown that women with PMDD have lower levels of cortisol and beta-endorphins during both the follicular and luteal phases. These observations suggest abnormalities in the hypothalamic-pituitary-gonadal axis in PMDD which is congruent with the findings of HPA-axis dysregulation in mood disorders.
Three Heads of PMDD Symptomatology
Symptom Expression Pattern
The length of time for which the women experience symptoms of PMDD varies from a few days to 2 weeks. For most symptomatic women, symptoms intensify 6 days before and are the most severe 2 days before the menses. Of all the symptoms mentioned, anger and irritability are the most distressing and are experienced slightly before the other symptoms.
As discussed, according to DSM-5, symptoms should be directly related to the menstrual cycle and must not merely represent an exacerbation of the symptoms of another disorder, such as major depressive disorder, panic disorder, dysthymic disorder, or a personality disorder (although the symptoms may be superimposed on those of these disorders). Prospective daily ratings must confirm symptoms during at least 2 consecutive symptomatic menstrual cycles. However, a provisional diagnosis may be made before this confirmation.
PMDD Assessment Scales
Treatment modalities for PMDD can be divided into 2 categories:
2. Pharmacological Methods
The symptoms for PMDD can overlap with other psychiatric disorders, most importantly major depression, and it is imperative to rule out another existing disorder before making the diagnosis of PMS/PMDD. The key factor in making the diagnosis is the temporal association of symptoms with the menstrual cycle. Some common differentials include:
Premenstrual dysphoric disorder is a well-recognized, severe form of PMS. It is imperative to establish a precise diagnosis of PMDD that is guided by the DSM-5 criteria. While the diagnosis of PMS is fairly common in females of reproductive age, the referring practitioner plays a pivotal role not only in distinguishing PMDD from PMS but also separating it from other psychiatric disorders like anxiety or depression. A good coordination between the primary physician, gynecologist, and psychiatrist is extremely important in the an interprofessional management of these patients. Educating the patients about the symptoms and encouraging them to maintain a diary for the accurate record of symptoms should be emphasized by each of treating physicians. It is worthwhile to have a therapist on board too who can help the patients by teaching them various coping skills to deal with the symptoms of anxiety and depression in addition to the medication management.
|||Yonkers KA,O'Brien PM,Eriksson E, Premenstrual syndrome. Lancet (London, England). 2008 Apr 5 [PubMed PMID: 18395582]|
|||Borenstein JE,Dean BB,Leifke E,Korner P,Yonkers KA, Differences in symptom scores and health outcomes in premenstrual syndrome. Journal of women's health (2002). 2007 Oct [PubMed PMID: 17937566]|
|||Wittchen HU,Perkonigg A,Pfister H, Trauma and PTSD - an overlooked pathogenic pathway for premenstrual dysphoric disorder? Archives of women's mental health. 2003 Nov [PubMed PMID: 14628182]|
|||Bertone-Johnson ER,Hankinson SE,Johnson SR,Manson JE, Cigarette smoking and the development of premenstrual syndrome. American journal of epidemiology. 2008 Oct 15 [PubMed PMID: 18701443]|
|||Bertone-Johnson ER,Hankinson SE,Willett WC,Johnson SR,Manson JE, Adiposity and the development of premenstrual syndrome. Journal of women's health (2002). 2010 Nov [PubMed PMID: 20874240]|
|||Dhingra V,Magnay JL,O'Brien PM,Chapman G,Fryer AA,Ismail KM, Serotonin receptor 1A C(-1019)G polymorphism associated with premenstrual dysphoric disorder. Obstetrics and gynecology. 2007 Oct [PubMed PMID: 17906010]|
|||Huo L,Straub RE,Roca C,Schmidt PJ,Shi K,Vakkalanka R,Weinberger DR,Rubinow DR, Risk for premenstrual dysphoric disorder is associated with genetic variation in ESR1, the estrogen receptor alpha gene. Biological psychiatry. 2007 Oct 15 [PubMed PMID: 17599809]|
|||Halbreich U,Borenstein J,Pearlstein T,Kahn LS, The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD). Psychoneuroendocrinology. 2003 Aug [PubMed PMID: 12892987]|
|||Hylan TR,Sundell K,Judge R, The impact of premenstrual symptomatology on functioning and treatment-seeking behavior: experience from the United States, United Kingdom, and France. Journal of women's health [PubMed PMID: 10565662]|
|||Halbreich U, The etiology, biology, and evolving pathology of premenstrual syndromes. Psychoneuroendocrinology. 2003 Aug [PubMed PMID: 12892990]|
|||Wyatt K,Dimmock P,Jones P,Obhrai M,O'Brien S, Efficacy of progesterone and progestogens in management of premenstrual syndrome: systematic review. BMJ (Clinical research ed.). 2001 Oct 6 [PubMed PMID: 11588078]|
|||Cunningham J,Yonkers KA,O'Brien S,Eriksson E, Update on research and treatment of premenstrual dysphoric disorder. Harvard review of psychiatry. 2009 [PubMed PMID: 19373620]|
|||Schmidt PJ,Nieman LK,Danaceau MA,Adams LF,Rubinow DR, Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. The New England journal of medicine. 1998 Jan 22 [PubMed PMID: 9435325]|
|||Björn I,Sundström-Poromaa I,Bixo M,Nyberg S,Bäckström G,Bäckström T, Increase of estrogen dose deteriorates mood during progestin phase in sequential hormonal therapy. The Journal of clinical endocrinology and metabolism. 2003 May [PubMed PMID: 12727949]|
|||Dhar V,Murphy BE, Double-blind randomized crossover trial of luteal phase estrogens (Premarin) in the premenstrual syndrome (PMS). Psychoneuroendocrinology. 1990 [PubMed PMID: 1966304]|
|||Oksa S,Luukkaala T,Mäenpää J, Toremifene for premenstrual mastalgia: a randomised, placebo-controlled crossover study. BJOG : an international journal of obstetrics and gynaecology. 2006 Jun [PubMed PMID: 16709215]|
|||Brzezinski AA,Wurtman JJ,Wurtman RJ,Gleason R,Greenfield J,Nader T, d-Fenfluramine suppresses the increased calorie and carbohydrate intakes and improves the mood of women with premenstrual depression. Obstetrics and gynecology. 1990 Aug [PubMed PMID: 2371034]|
|||Su TP,Schmidt PJ,Danaceau M,Murphy DL,Rubinow DR, Effect of menstrual cycle phase on neuroendocrine and behavioral responses to the serotonin agonist m-chlorophenylpiperazine in women with premenstrual syndrome and controls. The Journal of clinical endocrinology and metabolism. 1997 Apr [PubMed PMID: 9100599]|
|||Steinberg S,Annable L,Young SN,Liyanage N, A placebo-controlled clinical trial of L-tryptophan in premenstrual dysphoria. Biological psychiatry. 1999 Feb 1 [PubMed PMID: 10023508]|
|||Menkes DB,Coates DC,Fawcett JP, Acute tryptophan depletion aggravates premenstrual syndrome. Journal of affective disorders. 1994 Sep [PubMed PMID: 7798465]|
|||Roca CA,Schmidt PJ,Smith MJ,Danaceau MA,Murphy DL,Rubinow DR, Effects of metergoline on symptoms in women with premenstrual dysphoric disorder. The American journal of psychiatry. 2002 Nov [PubMed PMID: 12411222]|
|||Bancroft J,Cook A,Davidson D,Bennie J,Goodwin G, Blunting of neuroendocrine responses to infusion of L-tryptophan in women with perimenstrual mood change. Psychological medicine. 1991 May [PubMed PMID: 1876635]|
|||Eriksson O,Wall A,Marteinsdottir I,Agren H,Hartvig P,Blomqvist G,Långström B,Naessén T, Mood changes correlate to changes in brain serotonin precursor trapping in women with premenstrual dysphoria. Psychiatry research. 2006 Mar 31 [PubMed PMID: 16515859]|
|||Halbreich U,Tworek H, Altered serotonergic activity in women with dysphoric premenstrual syndromes. International journal of psychiatry in medicine. 1993 [PubMed PMID: 8514462]|
|||Smith SS,Ruderman Y,Frye C,Homanics G,Yuan M, Steroid withdrawal in the mouse results in anxiogenic effects of 3alpha,5beta-THP: a possible model of premenstrual dysphoric disorder. Psychopharmacology. 2006 Jun [PubMed PMID: 16193334]|
|||Sundström Poromaa I,Smith S,Gulinello M, GABA receptors, progesterone and premenstrual dysphoric disorder. Archives of women's mental health. 2003 Feb [PubMed PMID: 12715262]|
|||Sundström I,Ashbrook D,Bäckström T, Reduced benzodiazepine sensitivity in patients with premenstrual syndrome: a pilot study. Psychoneuroendocrinology. 1997 Jan [PubMed PMID: 9141149]|
|||Bhagwagar Z,Wylezinska M,Taylor M,Jezzard P,Matthews PM,Cowen PJ, Increased brain GABA concentrations following acute administration of a selective serotonin reuptake inhibitor. The American journal of psychiatry. 2004 Feb [PubMed PMID: 14754790]|
|||Sundström I,Bäckström T, Citalopram increases pregnanolone sensitivity in patients with premenstrual syndrome: an open trial. Psychoneuroendocrinology. 1998 Jan [PubMed PMID: 9618754]|
|||Pinna G,Costa E,Guidotti A, Fluoxetine and norfluoxetine stereospecifically and selectively increase brain neurosteroid content at doses that are inactive on 5-HT reuptake. Psychopharmacology. 2006 Jun [PubMed PMID: 16432684]|
|||Griffin LD,Mellon SH, Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes. Proceedings of the National Academy of Sciences of the United States of America. 1999 Nov 9 [PubMed PMID: 10557352]|
|||Batra NA,Seres-Mailo J,Hanstock C,Seres P,Khudabux J,Bellavance F,Baker G,Allen P,Tibbo P,Hui E,Le Melledo JM, Proton magnetic resonance spectroscopy measurement of brain glutamate levels in premenstrual dysphoric disorder. Biological psychiatry. 2008 Jun 15 [PubMed PMID: 18061146]|
|||Straneva PA,Maixner W,Light KC,Pedersen CA,Costello NL,Girdler SS, Menstrual cycle, beta-endorphins, and pain sensitivity in premenstrual dysphoric disorder. Health psychology : official journal of the Division of Health Psychology, American Psychological Association. 2002 Jul [PubMed PMID: 12090678]|
|||Joffe H,Kim DR,Foris JM,Baldassano CF,Gyulai L,Hwang CH,McLaughlin WL,Sachs GS,Thase ME,Harlow BL,Cohen LS, Menstrual dysfunction prior to onset of psychiatric illness is reported more commonly by women with bipolar disorder than by women with unipolar depression and healthy controls. The Journal of clinical psychiatry. 2006 Feb [PubMed PMID: 16566627]|
|||Young EA,Korszun A, The hypothalamic-pituitary-gonadal axis in mood disorders. Endocrinology and metabolism clinics of North America. 2002 Mar [PubMed PMID: 12055991]|
|||Pearlstein T,Yonkers KA,Fayyad R,Gillespie JA, Pretreatment pattern of symptom expression in premenstrual dysphoric disorder. Journal of affective disorders. 2005 Apr [PubMed PMID: 15780697]|
|||Meaden PM,Hartlage SA,Cook-Karr J, Timing and severity of symptoms associated with the menstrual cycle in a community-based sample in the Midwestern United States. Psychiatry research. 2005 Mar 30 [PubMed PMID: 15808287]|
|||Steiner M,Macdougall M,Brown E, The premenstrual symptoms screening tool (PSST) for clinicians. Archives of women's mental health. 2003 Aug [PubMed PMID: 12920618]|
|||Feuerstein M,Shaw WS, Measurement properties of the calendar of premenstrual experience in patients with premenstrual syndrome. The Journal of reproductive medicine. 2002 Apr [PubMed PMID: 12012879]|
|||Junghaenel DU,Schneider S,Stone AA,Christodoulou C,Broderick JE, Ecological validity and clinical utility of Patient-Reported Outcomes Measurement Information System (PROMIS®) instruments for detecting premenstrual symptoms of depression, anger, and fatigue. Journal of psychosomatic research. 2014 Apr [PubMed PMID: 24630180]|
|||Sundblad C,Hedberg MA,Eriksson E, Clomipramine administered during the luteal phase reduces the symptoms of premenstrual syndrome: a placebo-controlled trial. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 1993 Sep [PubMed PMID: 8216696]|
|||Sundblad C,Modigh K,Andersch B,Eriksson E, Clomipramine effectively reduces premenstrual irritability and dysphoria: a placebo-controlled trial. Acta psychiatrica Scandinavica. 1992 Jan [PubMed PMID: 1546547]|
|||Wikander I,Sundblad C,Andersch B,Dagnell I,Zylberstein D,Bengtsson F,Eriksson E, Citalopram in premenstrual dysphoria: is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle? Journal of clinical psychopharmacology. 1998 Oct [PubMed PMID: 9790157]|
|||Ravindran LN,Woods SA,Steiner M,Ravindran AV, Symptom-onset dosing with citalopram in the treatment of premenstrual dysphoric disorder (PMDD): a case series. Archives of women's mental health. 2007 [PubMed PMID: 17431739]|
|||Pearlstein TB,Stone AB,Lund SA,Scheft H,Zlotnick C,Brown WA, Comparison of fluoxetine, bupropion, and placebo in the treatment of premenstrual dysphoric disorder. Journal of clinical psychopharmacology. 1997 Aug [PubMed PMID: 9241004]|
|||Freeman EW,Rickels K,Sondheimer SJ,Polansky M, Differential response to antidepressants in women with premenstrual syndrome/premenstrual dysphoric disorder: a randomized controlled trial. Archives of general psychiatry. 1999 Oct [PubMed PMID: 10530636]|
|||Sundblad C,Wikander I,Andersch B,Eriksson E, A naturalistic study of paroxetine in premenstrual syndrome: efficacy and side-effects during ten cycles of treatment. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 1997 Aug [PubMed PMID: 9213079]|
|||Smith S,Rinehart JS,Ruddock VE,Schiff I, Treatment of premenstrual syndrome with alprazolam: results of a double-blind, placebo-controlled, randomized crossover clinical trial. Obstetrics and gynecology. 1987 Jul [PubMed PMID: 3299178]|
|||Harrison WM,Endicott J,Nee J, Treatment of premenstrual dysphoria with alprazolam. A controlled study. Archives of general psychiatry. 1990 Mar [PubMed PMID: 2407209]|
|||Beck LE,Gevirtz R,Mortola JF, The predictive role of psychosocial stress on symptom severity in premenstrual syndrome. Psychosomatic medicine. 1990 Sep-Oct [PubMed PMID: 2247559]|